# Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

> **NCT02721966** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 503 (actual)

## Conditions studied

- Axial Psoratic Arthritis

## Interventions

- **BIOLOGICAL:** Secukinumab
- **DRUG:** Secukinumab and Placebo

## Key facts

- **NCT ID:** NCT02721966
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-03
- **Primary completion:** 2019-06-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721966, "Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02721966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*